Cargando…
Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis
PURPOSE: Combined inhibition of CD28 and inducible T cell costimulator (ICOS) pathways with acazicolcept (ALPN-101) represents a potential new treatment for uveitis. Here, we evaluate preclinical efficacy using experimental autoimmune uveitis (EAU) in Lewis rats. METHODS: Efficacy was tested in 57 L...
Autores principales: | Wilson, Leslie, Lewis, Katherine E., Evans, Lawrence S., Dillon, Stacey R., Pepple, Kathryn L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064916/ https://www.ncbi.nlm.nih.gov/pubmed/36976157 http://dx.doi.org/10.1167/tvst.12.3.27 |
Ejemplares similares
-
Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023) -
Adalimumab in patients with vision-threatening uveitis: real-world clinical experience
por: Tang Lee Say, Timothy Lee, et al.
Publicado: (2021) -
Comprehensive LncRNA and Potential Molecular Mechanism Analysis in Noninfectious Uveitis
por: Lu, Shiheng, et al.
Publicado: (2023) -
Risk factors for ocular toxoplasmosis among uveitis patients in Kinshasa, DR Congo
por: Nsiangani Lusambo, Nadine, et al.
Publicado: (2023) -
Bibliometric analysis of the uveitis literature and research trends over the past two decades
por: Gao, Tingxiao, et al.
Publicado: (2023)